

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **SINOPHARM GROUP CO. LTD.\***

### **國藥控股股份有限公司**

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*

**(Stock Code: 01099)**

#### **ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2016**

Reference is made to the overseas regulatory announcement dated 21 October 2016 (the "**Announcement**") and issued by Sinopharm Group Co. Ltd. (the "**Company**") in relation to the third quarterly report for the nine months ended 30 September 2016 of China National Accord Medicines Corporation Ltd. ("**Sinopharm Accord**"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the nine months ended 30 September 2016 as set out in the Announcement.

**PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD**

Unit: Yuan  
Currency: RMB

	Current period-end	Period-end of last year	Increase/decrease	
Total assets	14,962,096,742.60	13,218,349,735.31	13.19%	
Net assets attributable to shareholder of listed company	6,067,416,420.30	5,453,393,694.55	11.26%	
	Current period	Increase/decrease in comparison with same period of last year	Year-begin to end of the Period	Increase/decrease in comparison with year-begin to Period-end of last year
Operating income	7,332,379,516.04	6.79%	21,421,432,387.92	8.85%
Net profit attributable to shareholders of the listed company	180,690,224.79	-3.25%	722,812,308.65	25.91%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	174,075,812.75	-4.89%	578,585,221.16	3.94%
Net cash flow arising from operating activities	--	--	530,039,802.32	29.86%
Basic earnings per share (RMB/Share)	0.498	-3.30%	1.993	25.90%
Diluted earnings per share (RMB/Share)	0.498	-3.30%	1.993	25.90%
Weighted average ROE	3.02%	-0.59%	12.56%	1.10%

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Wei Yulin**  
Chairman

Shanghai, the PRC

21 October 2016

*As at the date of this announcement, the executive directors of the Company are Mr. Wei Yulin and Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong, and Mr. Wu Yijian; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.*

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*